Fig. 1: Survival outcome following symptomatic COVID-19 infection in patients with MPN. | Leukemia

Fig. 1: Survival outcome following symptomatic COVID-19 infection in patients with MPN.

From: Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

Fig. 1

Kaplan–Meier estimate of survival for entire MPN patient cohort covering time from COVID-19 diagnosis censored at date of data submission (A). Effect of age (B), COVID-19 severity on admission according to WHO criteria (C), and MPN subtype (D). Effect of age by MPN subtype, each box represents a patient, solid fill box denotes survival and hatched box death (E). Effect of ruxolitinib treatment in patients aged over 75 years (F). ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis (including primary and secondary), O other MPN (including MDS/MPN overlap and MPN unclassifiable).

Back to article page